Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.16
-0.13 (-1.78%)
At close: Sep 26, 2025, 4:00 PM EDT
7.50
+0.34 (4.75%)
After-hours: Sep 26, 2025, 5:47 PM EDT
Gyre Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Gyre Therapeutics stock has a target of 18, which predicts a 151.40% increase from the current stock price of 7.16.
Price Target: $18.00 (+151.40%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 26, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Gyre Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +151.40% | Aug 26, 2025 |
Financial Forecast
Revenue This Year
125.21M
from 105.76M
Increased by 18.39%
Revenue Next Year
185.64M
from 125.21M
Increased by 48.26%
EPS This Year
0.13
from 0.05
Increased by 175.81%
EPS Next Year
0.28
from 0.13
Increased by 111.54%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 131.8M | 249.9M | |
| Avg | 125.2M | 185.6M | |
| Low | 117.6M | 123.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 24.6% | 99.6% | |
| Avg | 18.4% | 48.3% | |
| Low | 11.2% | -1.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.18 | 0.54 | |
| Avg | 0.13 | 0.28 | |
| Low | 0.09 | 0.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 271.3% | 303.8% | |
| Avg | 175.8% | 111.5% | |
| Low | 83.5% | -70.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.